<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388075</url>
  </required_header>
  <id_info>
    <org_study_id>HMO-0451-10</org_study_id>
    <nct_id>NCT01388075</nct_id>
  </id_info>
  <brief_title>Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The genetic factors associated with variability in CYP2C9 induction have not been elucidated.
      The hypothesis underlying this study is that following 7 days treatment with rifampicin, a
      known CYP450 inducer, the genetic variability in regulatory elements controlling CYP2C9
      expression will be associated with the magnitude of change in INR response to warfarin and in
      CYP2C9-mediated warfarin metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Normalized Ratio (INR)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Warfarin concentration</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Rifampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consecutive treatments with rifampicin and placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>oral, 450 mg/day , 7 days</description>
    <arm_group_label>Rifampicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

        Exclusion Criteria:

          -  Consumption of any medication during 30 days

          -  Smoking

          -  Alcohol consumption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mordechai Muszkat, MD</last_name>
    <phone>972-6777111</phone>
    <phone_ext>73793</phone_ext>
    <email>muszkatm@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mordechai Muszkat, MD</last_name>
      <phone>972-2-6777111</phone>
      <phone_ext>73793</phone_ext>
      <email>muszkatm@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Mordechai Muszkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>July 5, 2011</last_update_submitted>
  <last_update_submitted_qc>July 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mordechai Muszkat, MD</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>induction</keyword>
  <keyword>CYP2C9</keyword>
  <keyword>Genetic variability</keyword>
  <keyword>Expression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

